Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy

Figure 6

Analysis of leukocytes (a) during therapy and ((b), (c)) after necropsy from Balb/c mice. Blood samples of animals were taken on day 10 after start of therapy. At necropsy, blood samples and spleens were obtained and analyzed by flow cytometry. Given are the percentages of CD166 and CD62L positive cells. Control animals received equivalent volumes of PBS (𝑛=7). Values are given as mean + SD; 𝑃<0.05 versus saline; t-test. Significant data for CD166 (ALCAM) were achieved in the blood at d10 in animals treated with Irinotecan (𝑃=0.032) and R848 + LPS (0.035) and additionally in the spleen at d17 in the LPS group (𝑃=0.004). For CD62L (L-Selectin), significance was reached in the spleen at d17 for R848 + Taxol (𝑃=0.002) and Taxol + LPS (0.038).

(a)

(b)

(c)